Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18488198 | 0.87 | EDNRA (0.48) | EDNRAKDM4EMEN1CYP3A4CYP2C9 | |
| SCHEMBL18488197 | 0.85 | EDNRA (0.48) | EDNRAKDM4EMEN1CYP3A4CYP2C9 | |
| SCHEMBL18488193 | 0.80 | CA2 (0.39) | EDNRAKDM4EMEN1CYP3A4CYP2C9 | |
| SCHEMBL16684681 | 0.80 | EDNRA (0.56) | EDNRAKDM4ETSHRHSD17B10BCL2 | |
| SCHEMBL18488194 | 0.72 | EDNRA (0.47) | EDNRAKDM4EMEN1CYP3A4CYP2C9 | |
| SCHEMBL18488202 | 0.72 | EDNRA (0.49) | EDNRAKDM4ETSHRHSD17B10 | |
| SCHEMBL28416676 | 0.72 | EDNRA (0.60) | EDNRAKDM4EMEN1CYP3A4CYP2C9 | |
| SCHEMBL10714752 | 0.71 | EDNRA (0.60) | EDNRAKDM4ETSHRHSD17B10BCL2 | |
| SCHEMBL20434656 | 0.70 | EDNRA (0.41) | EDNRAKDM4EMEN1CYP3A4CYP2C9 | |
| SCHEMBL13713848 | 0.70 | BCL2 (0.56) | EDNRAKDM4ETSHRHSD17B10BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247751-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| US-20190077755-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2019-03-14 | — | — | US | disclosed |
| US-10173978-B2 | Small molecule androgen receptor inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180215712-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2017023916-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215712-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885MEN1 3004/4885 |
| US-20190077755-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885MEN1 3004/4885 |
| US-20200247751-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885MEN1 3004/4885 |
| US-10173978-B2 | Small molecule androgen receptor inhibitors and methods of use thereof | AR, KLK3, BRDT | EDNRA 338/4885KDM4E 1811/4885MEN1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.